BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 September 1997.
The new agreement grants to Merck licenses and options to license Vical's naked DNA technology to deliver growth factors as potential treatments for a range of applications including revascularization. The agreement marks the first license of Vical's naked DNA technology for potential delivery of a therapeutic protein, and is the first such agreement since the issuance of Vical's broad patents covering the technology. Vical had previously licensed the technology to Merck and others for use in vaccines against a total of 13 infectious diseases.
Vical scientists and collaborators discovered that direct administration of naked DNA can result in the expression of the protein encoded by the genetic material and proposed the application of this discovery to vaccine research. Vical and Merck scientists published the initial demonstration of naked DNA technology in a preclinical model and have demonstrated its application as a novel vaccination technique in a variety of animal infectious disease models. Merck is currently conducting early clinical trials of a naked DNA vaccine.
Alain B. Schreiber, M.D., Vical's President and CEO, said, "Merck has been the leader in developing naked DNA vaccines, and we are delighted that Merck has decided to broaden its applications for Vical's naked DNA technology. Through this and other potential collaborative agreements, we hope to expand the scientific and financial potential of this promising platform technology."
The revascularization regimen would involve administration of specific genes into tissues where disease had restricted blood flow. Administration of the genes may increase local production of certain growth factors which may stimulate the growth of new blood vessels. The newly formed blood vessels may restore blood flow to the affected areas. This treatment may be applicable in diseases such as coronary artery and peripheral vascular ischemias.
Vical Incorporated is focused on the development of gene-based pharmaceutical product candidates for human therapy. Vical's gene-based therapeutic approach may offer safer and more cost-effective alternatives for many diseases, including cancer, infectious diseases and metabolic disorders.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether any product candidates will be discovered or, if discovered, whether any will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical will receive any additional funds under the agreement with Merck, and additional risks set forth in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
--30--sig/ix*
CONTACT: Vical Incorporated, San Diego Alan R. Engbring or Robert H. Zaugg, 619/453-9900
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970915
BW970910
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .